MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Pharmaceuticals, Biotechnology & Drugs
Immunocore Holdings plc (NASDAQ: IMCR)*
Organization & Developments: Immunocore
Parents
Immunocore Holdings plc (NASDAQ: IMCR)*
Children
*British clinical-stage biotechnology company which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology
2014: AstraZeneca struck deals with UK's Immunocore for Cancer Drug (2014)
2022: Immunocore Holdings (IMCR) Investor Presentation - Slideshow_ seekingalpha.com
2022: Immunocore: Attractive Commercial-Stage Biopharma_seekingalpha.com
2023: Immunocore: First Half Of 2024 IMC-F106C Data Expected
2024: Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
2024: Immunocore Holdings: Vulnerable To Profit Taking After Big Rally_ seekingalpha.com
2024: Immunocore Is Adequately Valued, But Its Prospects Are Uncertain_seekingalpha.com
2024: Immunocore's KIMMTRAK Wins NHS Funding for Rare Melanoma Treatment
2024: SWOT analysis: biotech stock faces pivotal moment amid PRAME data Investing.com
2025: Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Jumps
Finance & Acquisitions: Immunocore
Key People: Immunocore